Bimekizumab plus certolizumab pegol further reduced disease activity score 28-joint count C-reactive protein (DAS28(CRP)) for RA patient in a phase II study, but more messages about the efficacy and safety is lack (110). The gene discussed is CRP; the disease is rheumatoid arthritis.